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Abstract
Regulatory noncoding RNAs (ncRNAs) are a class of RNAs transcribed by regions of the human genome that do not
encode for proteins. The three main members of this class, named microRNA, long noncoding RNA, and circular RNA
play a key role in the regulation of gene expression, eventually shaping critical cellular processes. Compelling
experimental evidence shows that ncRNAs function either as tumor suppressors or oncogenes by participating in the
regulation of one or several cancer hallmarks, including evading cell death, and their expression is frequently
deregulated during cancer onset, progression, and dissemination. More recently, preclinical and clinical studies
indicate that ncRNAs are potential biomarkers for monitoring cancer progression, relapse, and response to cancer
therapy. Here, we will discuss the role of noncoding RNAs in regulating cancer cell death, focusing on those ncRNAs
with a potential clinical relevance.
Facts
● Many of the genetic and epigenetics alterations in
human cancers are found in noncoding regions of
the DNA.
● miRNAs and lncRNAs have been largely described in
their role in controlling epithelial tissues homeostasis,
both in physiological and pathological conditions
such as cancer.
● The clinical application of ncRNAs is already under
evaluation in ongoing clinical trials exploring their
role as biomarkers for patient survival, metastasis
development prediction, or therapy response.
Open questions
● What is the role of regulatory ncRNA in pyroptosis,
ferroptosis, and autophagy?
● What is the functional interplay between miRNA,
lncRNA, and circRNA in cancer biology?
● How can we integrate preclinical findings to select
the best regulatory ncRNA for clinical studies?
Introduction
Protein-coding genes undoubtfully play an established
role in cancer transformation and progression, however,
recent compelling evidence is highlighting a role for
noncoding RNAs. There is no question that loss or
mutation of crucial genes are frequent events in cancer
biology: the mutation of the tumor suppressor gene p53 is
observed in almost 50% of human cancers1–7, and the
amplification of the oncogene MYC8 or the translocation
of BCL-2 gene9–12 are crucial drivers in various cancer
contexts13–16. However, many of the recurrent genetic
and epigenetic alterations are found in genes that do not
codify for proteins but that codify for an entire class of
molecules called noncoding RNAs (ncRNAs), which play
a key role in the regulation of many cellular activities.
The non-protein-coding regions of the human genome
are transcribed into molecules of RNA classified as reg-
ulatory noncoding RNAs17. ncRNAs are mainly tran-
scribed by RNA polymerase II and share several
characteristics with messenger RNAs (mRNAs). Indeed,
they have a cap structure at the 5′ end, a poly(A) tail at the
3′ end and their expression is controlled by canonical
promoter elements and transcription factors. Con-
ventionally, regulatory ncRNAs are classified either as
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Massimiliano Agostini (m.agostini@med.uniroma2.it) or
Eleonora Candi (candi@uniroma2.it) or Gerry Melino (gm614@mrc-tox.cam.ac.uk)
1Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”,
00133 Rome, Italy
2IDI-IRCCS, Via Monti di Creta 106, 00166 Rome, Italy
Full list of author information is available at the end of the article.
Edited by I. Amelio


































small ncRNAs, if they are shorter than 200 ribonucleo-
tides or as long noncoding RNAs (lncRNAs), longer than
200 ribonucleotides. Small ncRNAs include microRNAs
(miRNAs), which mediates post-transcriptional RNA
silencing, piwiRNAs, which regulate chromatin mod-
ifications and transposons repression, as well as the more
recent circular RNAs (circRNAs)18.
In this review, we shall discuss the role of ncRNAs in
regulating cancer cell death (Table 1)19. In particular, we
will describe those regulatory ncRNAs that have been
largely investigated, on the basis of both in vitro and
in vivo evidence as clinical data.
Epithelial ncRNAs
Recently, miRNAs and lncRNAs have gained significant
attention for their role in controlling epithelial tissue
homeostasis in normal and pathological conditions, being
key regulators of epithelial progenitor stem cells prolifera-
tion, somatic lineage specification, and differentiation20,21.
Distinct miRNAs control epidermal development, epi-
dermal differentiation, and adult stem cells maintenance
(for reviews see refs. 22,23). These include the miR-20
family, miR-24, the miR-200 family, miR-205, and miR-
20324–28. The latter has been described in his mechanistic
role in the control of epithelial progenitor cells pro-
liferation and in the inhibition of cellular senescence,
having as a target one of the epithelial master genes, the
transcription factor TP6324,29. Interestingly, these
epithelial-specific miRNAs have also been implicated in
controlling key regulators genes of the pathogenesis of
many adenocarcinomas and squamous cell carcinomas
(SCC)30. As an example, the miR-200 family, controlling
the expression of ZEB1 and ZEB2, have been described in
the epithelial-to-mesenchymal transition (EMT) in ovar-
ian cancer and SCCs. Moreover, miR-203, targeting
ABL1, SOCS3, and ZEB3, controls EMT in epithelial
cancers28,31. miRNAs also play a key role in epithelial cells
upon different environmental stressors, such us UV
radiations and inflammation32–36.
Only a few lncRNAs have been studied so far in the
regulation of epithelial development, such as ANCR, an
anti-differentiation lncRNA, and TINCR, a terminal
differentiation-induced lncRNA; however, the mechanism
through which they maintain the cell of the epidermis in a
undifferentiated state has not been identified yet37,38.
Similarly, LIN00941 has also been implicated in the
control of epidermal homeostasis repressing the expres-
sion of pro-differentiation genes through a not-yet iden-
tified mechanism39. Moreover, the pro-differentiation
lncRNA, uc.291, has been shown acting as a pro-
differentiation transcript by facilitating the activation/
binding of the chromatin remodeling complex SWI/SNF
(BAF) in proximity to the epidermal differentiation
complex (EDC) genes to allow their expression40.
While several studies investigated the specific con-
tributions of miRNAs in epithelial cancer development,
Table 1 Pro-apoptotic and anti-apoptotic ncRNAs.
ncRNA PRO-apoptotic role Cellular/animal model Relevant references (original papers)
Let-7 • Inhibition of BCL2L1





miR-15/16 • Repression of BCL-2 and BMI1 • Chronic lymphatic leukemia
• Mantle cell lymphoma
Cimmino et al.52
Teshima et al.53
miR-34 • Regulation of proteins involved in cell death: BCL-2,









miR-29 • Repression of MCL-1 expression • Acute myeloid leukemia Garzon et al.76
GAS5 • Induction of apoptosis in a mouse model • Brest cancer (mouse) Mourtada-Maarabouni et al.103
MEG3 • Induction of p53 • Colorectal cancer Zhou et al.108
NIKLA • Activation of apoptosis in tumor-specific CTLs • Breast cancer and lung cancer Huang et al.113
NEAT1a • Enhanced apoptosis after DNA damage • Chronic lymphocytic leukemia Blume et al.116
circFOXO3 • Increased PUMA expression • Breast cancer (mouse) Du et al.147
ncRNA ANTI-apoptotic role Cellular/animal model Relevant references (original papers)
miR-21 • expression of pro-apoptotic genes: APAF11, PDCD4,
RHOB, and FASLG
• Non-small cell lung cancer Hatley et al.84




miR-221 • Increased apoptosis and cell-cycle arrest • Hepatocellular carcinoma Park et al.98
CCAT • Interaction with p63 and SOX2 • Squamous cell carcinoma Jiang et al.123
FAL1 • Interaction with BMI1 • Pan-cancer database Hu et al.128
PVT1 • Downregulation of Caspase-7, Caspase-9, and PARP • Nasopharyngeal carcinoma He et al.132
aControversial role since NEAT1 has also been correlated to an oncogenic activity in some tumor types.
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the role of lncRNAs in this context has not been inves-
tigated thoroughly yet.
microRNAs with pro-apoptotic functions
let-7
let-7 has been one of the first miRNAs isolated and
characterized in the nematode C. elegans. The human
genome contains 13 let-7 family member genes, which are
distributed in different genomic loci and codify for 9
mature miRNAs41. Let-7 expression is downregulated in
many cancers, such as lung, breast, pancreatic cancer, and
melanoma and in many cancer-associated clinical condi-
tions like cholestasis42. Moreover, downregulation of let-7
expression correlates with poor survival in lung cancer43,
ovarian cancer44, and head and neck SCC patients45.
Functionally, let-7 acts as a tumor suppressor partially
through the downregulation of several genes involved in
cell death, as shown by the ectopic expression of let-7
resulting in the inhibition of BCL2L1 in colorectal can-
cer46 or by the induction of apoptosis via upregulation of
BAK and BAX and downregulation of BCL-XL protein
levels47. Although in vivo delivery of let-7 in mouse
models of lung cancer demonstrated its therapeutic
potential, its tumor suppressor functions might be asso-
ciated with repression of cell proliferation and elimination
of cancer cells mainly through a non-apoptotic
mechanism48.
miR-15/16
miR-15 and miR-16 are localized on chromosome
13q14. This chromosomic region is frequently deleted in
B-cell chronic lymphocytic leukemia (B-CLL)49. miR-15
and miR-16 are found in a 30-kb region, which is lost in
CLL, and both genes are either deleted or downregulated
in most of CLL cases (~68%)50. However, several studies
suggested that miR-15/16 could be also downregulated by
additional mechanisms, such as defective DROSHA pro-
cessing or epigenetic alterations51. The tumor suppressor
action of miR-15/16 is the result of the induction of cell
death through the repression of the anti-apoptotic pro-
teins BCL-2 and BMI1 (Fig. 1a)52–57. More recently, the
tumor suppressor function of miR-15/16 has also been
observed in solid tumors such as mesothelioma58 or
chondrosarcomas59, where its expression is suppressed in
order to promote tumor neo-angiogenesis. Moreover, the
miR-15/16 knockout mouse model supports the in vivo
tumor suppressor activity of miR-15/16. Indeed, deletion
of miR-15/16 gene results in B cells proliferation and in
the development of lymphoid malignancies60,61.
miR-34
The miR-34 family consists of three different transcripts
miR-34a, miR-34b, and miR-34c with high sequence
homology.
In humans, the miR-34a gene is located on the chro-
mosomal region 1p36.22, which is frequently deleted in
many human cancers, including neuroblastoma, glioma,
breast cancer, lung cancer, colorectal cancer, and mela-
noma62–64. The miR-34b and miR-34c genes are both
encoded on chromosome 11q23.1, and rearrangements of
this region have been observed in several solid tumors and
in hematological malignancies65. Both in vitro and in vivo
studies have shown that the miR-34 family genes (in
particular miR-34a) act as tumor suppressors: when
overexpressed they repress several oncogenes, resulting in
an increased cancer cell death and in an inhibition of
metastasis development. miR-34a has also been shown to
play a role in the regulation of NF-κB in CD8+ T cells,
promoting their cytotoxic activity66. In the context of cell
death, miR-34 family acts on proteins such as BCL-2,
BIRC5 (Survivin), CREB, and YY1, which are involved in
apoptosis regulation (Fig. 1b)67–71.
Nevertheless, it should be noted that miR-34-deficient
animals are not showing increased susceptibility to either
spontaneous or to irradiation-induced nor MYC-initiated
tumorigenesis.
Strikingly in 2013, a miR-34 mimic (MRX34) became the
first microRNA tested in a phase 1 clinical trial
(NCT002862145). In particular, a liposomal miR-34
mimetic was administered intravenously to patients with
unresectable liver cancer or metastatic cancer refractory to
standard treatment, with or without liver involvement.
From these studies, MRX34 treatment was associated with
antitumor activity and acceptable safety, but subsequent
monitoring showed immune-related toxicities. To date, it
is not clear whether further clinical trials will be started72.
miR-29
The miR-29 family is composed of three isoforms. miR-
29b-1 and miR-29a form one cluster on chromosome
7q32, while miR-29b-2 and miR-29c form a second
cluster on chromosome 1q23. Of note that the first cluster
region is frequently deleted in myelodysplastic syndromes
and therapy-related acute myeloid leukemia (AML)73,74.
In addition, several experimental observations showed
that miR-29 family is downregulated in chronic lympho-
cytic leukemia, lung cancer, invasive breast cancer, and
cholangiocarcinoma. miR-29 functions as a tumor sup-
pressor gene in several cancer types. Indeed, ectopic
expression of miR-29b induced apoptosis in cholangio-
carcinoma cell lines and reduced tumorigenicity in a
xenograft model of lung cancer, rhabdomyosarcoma, and
AML75. Mechanistically, miR-29 induces cell death by
directly repressing the expression of the anti-apoptotic
BCL-2 family member, MCL-1 (Fig. 1c)76. In addition,
modulation of miR-29 expression results in the upregu-
lation of some pro-apoptotic genes, such as BIM and the
tumor suppressor programmed cell death-4 (PDCD4) in
Agostini et al. Cell Death Discovery            (2020) 6:13 Page 3 of 12
Official journal of the Cell Death Differentiation Association
AML, and also inhibits the expression of DNMT3B in
hepatocarcinoma cell lines77. Interestingly, MCL-1
mRNA inversely correlated with miR-29a or miR-29b
expression in 45 primary AML samples78.
microRNAs with anti-apoptotic functions
miR-21
The human miR-21 gene is located in the fragile site
FRA17B on chromosome 17q23.279. Expression profile
studies on tumor samples, including lung, breast, sto-
mach, prostate, colon, pancreatic tumors, and B-cell
lymphomas showed that miR-21 is the most commonly
upregulated miRNA in solid tumors and hematological
malignancies, indicating miR-21 as an “oncomiR”80–82.
Indeed, functional studies in several cancer cell lines
demonstrated that knockdown of miR-21 activates cas-
pases leading to apoptotic cell death. Moreover, in vitro
evidence also suggested a positive regulatory role in pyr-
optosis through the activation of the NLRP3 inflamma-
some83. At a molecular level, miR-21 suppresses the
expression of pro-apoptotic genes, such as APAF11,
PDCD4, RHOB, and FASLG (Fig. 2a)84. The oncogenic
role of miR-21 was also confirmed in vivo by generating
conditionally expressing miR-21 mice84. This mouse
model demonstrated that miR-21 is capable of initiation,
maintenance, and prolonged survival of tumors in vivo
and demonstrated the importance of miR-21 in hemato-
logical malignancies85.
miR-155
The human gene miR-155 is localized on chromosome
21 within an exon of a noncoding RNA, from the B-cell
Integration Cluster (BIC)86. miR-155 is mainly expressed
in lymphoid tissues, including thymus and spleen, where
it regulates several physiological functions of these organs,
such as antibodies and cytokines production87. In addi-
tion, several observations have shown that miR-155 is
accumulated in non-Hodgkin lymphomas, as in the
Fig. 1 microRNAs with pro-apoptotic functions and relative
inhibited molecular pathways. a miR-15/16 expression is
deregulated in hematological malignancies and induces cell death by
inhibiting the expression of the anti-apoptotic protein BCL-2 and
BMI1. b miR-34a acts as a tumor suppressor gene by directly
repressing the expression of several proteins involved in the
regulation of cell survival. c miR-29a regulates the critical anti-
apoptotic genes MCL-1. MCL-1 is an anti-apoptotic protein that
promotes cancer cell survival and proliferation, and it is frequently
overexpressed in AML. It has been also shown that miR-29 can induce
cell death by inducing the expression of pro-apoptotic proteins,
including BIM and PDCD4. BCL-2 B-cell lymphoma 2 gene, BMI1
polycomb complex protein BMI1, MCL-1 induced myeloid leukemia
cell differentiation protein, BIM BCL-2-like protein 11, PDCD4
programmed cell death protein 4, AML acute myeloid leukemia.
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diffuse large B-cell lymphomas, and Burkitt lymphomas
and in Hodgkin lymphomas88–90. The oncogenic role of
miR-155 was confirmed by the generation of genetically
modified mice, developing B-cell lymphoma upon its
overexpression. Among the molecular mechanisms
underlying its oncogenic properties, the direct repression
of SH2-containing inositol phosphatase (SHIP-1) (Fig.
2b)91,92, a positive regulator of apoptosis, seems to play a
pivotal role. Apart from hematologic malignancies, miR-
155 is also overexpressed in several solid tumors, such as
breast, colon, pancreatic, and lung cancer, and has also
been described in the regulation of autophagy in an
experimental mouse model of pancreatitis93. More
recently, the therapeutic efficacy of an anti-miR-155 was
tested in vivo by using a novel delivery system targeting
the acidic tumor microenvironment: a nucleic acid anti-
miR-155 linked to a peptide with a low pH-induced
transmembrane structure (pHLIP) effectively inhibited
miR-155 expression after intravenous administration,
leading to cancer regression in a mouse model of
lymphoma94.
miR-221
miR-221/222 is a microRNA with oncogenic properties,
highly conserved in vertebrates, located on the X chro-
mosome in humans, mice, and rats. Overexpression of
miR-221/222 has been observed in several human
malignancies, including hepatocellular carcinoma, breast,
prostate, pancreatic cancer, and glioblastoma95,96. The
oncogenic activities of miR-221 were also confirmed
in vivo as the overexpression of miR-221 in p53−/−; Myc
liver progenitors stimulates tumor onset and progres-
sion97. The oncogenic activity of miR-221 might be par-
tially explained by the repression of PUMA and BIM
proteins (Fig. 2c). Interestingly, in vivo preclinical studies
showed that a cholesterol-modified isoform of anti-miR-
221 significantly reduced miR-221 levels in livers after
injection, reducing tumor cell proliferation, and increasing
the expression of apoptosis and cell-cycle arrest markers,
eventually prolonging mice survival98. Although miR-221
is classified as an “oncomiR”, it should be noted that his
role as tumor suppressor gene has also been observed99.
Long noncoding RNAs
Long noncoding RNAs are classified as endogenous
ncRNAs longer than 200 nucleotides. They are tran-
scribed by RNA polymerase II from an independent
promoter and processed as coding RNAs. Indeed, they are
capped, spliced, and polyadenylated, however, lncRNAs
lack a significant open-reading frame. Compared with
protein-coding transcripts, lncRNAs are overall expressed
at lower levels and they are not highly evolutionarily
conserved, with only 5–6% of lncRNAs harboring con-
served sequences100.
Fig. 2 microRNAs with anti-apoptotic functions and relative inhibited molecular pathways. amiR-21 is the most upregulated oncomiR in solid
tumors and hematological malignancies. The oncogenic activity of miR-21 is associated with the direct negative regulation of pro-apoptotic genes,
such as APAF11, PDCD4, RHOB, and FASLG. b miR-155 plays a key role in the regulation of the immune response. miR-155 is upregulated in B-cell
lymphomas and by targeting SHIP-1 supports cell survival. c In liver cancer, miR-221 exerts oncogenic activity by repressing the expression of the
apoptotic proteins PUMA and BIM. APAF11 apoptotic protease activating factor 1, PDCD4 programmed cell death protein 4, RHOB Ras Homolog
Family Member B, FASLG Fas ligand, SHIP-1 Src homology 2-SH2 domain containing inositol polyphosphate 5-phosphatase 1, PUMA p53 upregulated
modulator of apoptosis, BIM BCL-2-like protein 11.
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Several studies have described a range of molecular
mechanisms by which lncRNAs may exert their functions.
In particular, lncRNAs have been described as molecular
scaffolds or architectural RNAs in a variety of cellular pro-
cesses, among which epigenetics modifications, alternative
splicing, mRNA translation, and maintenance, and acting as
decoys or “sponges” for miRNAs or transcription factors.
lncRNAs with pro-apoptotic function
GAS5
The growth arrest-specific transcript 5 (GAS5) is located
at 1q25, and the gene transcribed contains 12 exons that do
not encode for functional proteins101. GAS5 is a tumor
suppressor gene, and is one of the most expressed lncRNAs
in all human tissues102. The expression of GAS5 in cancers
is significantly reduced. Reduced expression has been
observed in breast, prostate, head and neck, gastric, color-
ectal, pancreatic, and cervical cancer, and more importantly,
its expression is negatively correlated with clinical–
pathological characteristics, such as tumor size, staging, or
metastasis. Moreover, in vivo studies have shown inhibition
of breast tumor growth by inducing cell-cycle arrest and
apoptosis after the overexpression of GAS5 in breast cancer
cell lines and their subsequent injection in nude mice103.
Several molecular mechanisms of action for GAS5 have
been proposed, including inhibition of translation and
decoy or miRNA sponge activity. The decoy function of
GAS5 has been shown in HeLa and HepG2 cell lines, and
seems to be its major mechanism of action. Indeed, GAS5
interacts with the DNA-responsive elements of glucocorti-
coids receptor preventing the binding of the receptor to the
DNA, thereby blocking the activation of target genes tran-
scription (Fig. 3a)104. Moreover, GAS5 can also interact
with other steroid hormone receptors including progester-
one and androgen receptors, which play important roles in
hormone-dependent cancers102.
MEG3
Maternally expressed gene 3 (MEG3) located on the
human chromosome region 14q32.3 is expressed in many
normal tissues105. However, MEG3 expression is lost in
several human tumors including osteosarcoma, hepato-
cellular cancer, gastric cancer, and non-small cell lung
cancer (NSCLC) by promoter or intergenic differentially
methylated region hypermethylation, suggesting that loss
of MEG3 expression contributes to tumor development in
several tissues106,107. Importantly, patients with lower
levels of MEG3 expression had a relatively poor prognosis.
MEG3 functions as a tumor suppressor gene, and its re-
expression inhibits cell proliferation and promotes apop-
tosis in human glioma and NSCLC cell lines. At a mole-
cular level, MEG3 function is mediated, at least partially,
by the activation of the tumor suppressor gene p53 by the
downregulation of MDM2 expression108–110.
NKILA
The human gene that encodes NKILA, an NF-κB-
interacting lncRNA, is located on chromosome 20.
NKILA is downregulated in breast cancer, nasopharyngeal
carcinoma, and melanoma111. In addition, reduced
NKILA expression is associated with breast cancer
metastasis and poor patient prognosis112. Mechanistically,
the transcription factor NF-κB upregulates the expression
of NKILA, which in turn binds to NF-κB/IκB, and directly
masks the phosphorylation motifs of IκB, resulting in the
inhibition of IKK-induced IκB phosphorylation, and NF-
κB activation, forming a negative regulatory loop (Fig. 3b).
This regulatory mechanism is promoting tumorigenesis
by inhibiting apoptosis and increasing invasion. More
recently, NKILA has also been shown to regulate T-cells
activation by inhibiting NF-κB activity, and ectopic
expression of NKILA in tumor-specific CTLs and
TH1 cells correlated with apoptosis and shorter patient
overall survival113.
NEAT1
The Homo sapiens nuclear paraspeckle assembly tran-
script 1 (NEAT1) sequence is a product of the NEAT1
gene, which is located on chromosome 11. NEAT1 has
been identified as a p53 target gene that plays an impor-
tant role in the formation of paraspeckles, and is indis-
pensable for cell-cycle arrest and apoptosis in response to
genotoxic stress114. Therefore, it has a key function in
suppressing neoplastic transformation and cancer onset.
Indeed, in a pancreatic cancer mouse model, NEAT1
deficiency increased transformation and contributed to
the development of premalignant pancreatic intraepithe-
lial neoplasia and cystic lesions through global changes in
gene expression115. Moreover, NEAT1 expression is
downregulated in several cancers, while increased NEAT1
levels are correlated with better overall survival in color-
ectal cancer patients. In addition, elevated NEAT1 levels
have been associated with enhanced apoptosis after DNA
damage by irradiation of chronic lymphocytic leukemia
cells116,117. However, NEAT1 role is controversial since
several studies also characterized its oncogenic activity. As
matter of fact, during tumorigenesis NEAT1 levels are
increased, and high levels of NEAT1 were associated with
worse prognosis in gastric adenocarcinoma and laryngeal
SCC118,119. Accordingly, modulation of NEAT1 expres-
sion promotes cell survival and/or proliferation of human
cancer cell lines120, and NEAT1 acts as an oncogene in a
mouse model of skin carcinogenesis114. At a molecular
level, one possible mechanism by which NEAT1 exerts its
oncogenic role, at least in ovarian cancer, is the interac-
tion with the tumor suppressor miRNA miR-34a-5p,
acting as a sponge and negatively regulating miR-34a
expression.
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Overall, NEAT1 can elicit a context-specific function in
either promoting or suppressing neoplastic transformation.
lncRNAs with anti-apoptotic functions
CCAT
Colon cancer-associated transcript (CCAT) is located
within the 8q.24.21 genomic region that is frequently
amplified in colorectal cancer (CRC)121,122. Expression
profile studies highlight that CCAT1 and CCAT2 genes
are frequently overexpressed in CRC, and their expression
is associated with shorter progression-free and overall
survival.
The oncogenic function of CCAT is the result of the
activation of genes involved in cell proliferation and in
the inhibition of apoptosis. Indeed, CCAT regulates the
overexpression of MYC, possibly through its physical
interaction with TCF7L2, leading to genomic instability
and promoting cell growth (Fig. 4a). In addition, a second
possible molecular regulatory mechanism has been
observed in SCC; in this context, CCAT regulates tran-
scription of genes involved in cell proliferation and
survival by a physical interaction with both transcription
factors p63 and SOX2123. (Fig. 4b). Finally, overexpression
of CCAT has been observed in other types of cancer,
including gastric, breast, and lung cancer124.
FAL1
The gene encodes for focally amplified LncRNA on
chromosome 1 (FAL1), and is localized at the chromo-
somal region 1q21.2. FAL1 functions as an oncogene in
several cancers, and is upregulated in ovarian, thyroid
cancer and NSCLC125,126. In addition, FAL1 expression
correlates with some clinical and pathological character-
istics of NSCLC and ovarian cancer patients. Both in vitro
and in vivo studies demonstrated that the biological
function of FAL1 is to regulate cell cycle, cell death,
migration, and invasion127. Mechanistically, FAL1 inter-
acts with the epigenetic repressor BMI1 and modulates
the transcription of a number of genes involved in cell-
cycle arrest and apoptosis, such as CDKN1A, FAS, BTG2,
TP53I3, FBXW7, and CYFIP2128 (Fig. 4c).
Fig. 3 lncRNAs as inducers of cell death and relative molecular mechanisms. a GAS5 prevents GR-dependent gene activation by binding to the
glucocorticoids receptor (GR) functioning as a decoy. b NF-κB is a key transcription factor in the regulation of cell survival. NKILA binds IkB and
prevents its phosphorylation resulting in the inhibition of NF-κB activation, thereby repressing NF-κB target genes involved in cell survival. GAS5
growth arrest-specific transcript 5, GR glucocorticoids receptors, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, IkB inhibitor of
kappa B.
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PVT1
The human PVT1 gene is located in the human chro-
mosome 8q24 region close to the well-established onco-
gene MYC129. Interestingly, the amplification of 8q24 is a
frequent event in a vast variety of cancers including CRC,
where it is also associated with clinical findings of
decreased overall survival130,131. PVT1 functions as an
oncogene by inhibiting the apoptosis of tumor cells,
promoting cell proliferation, and affecting tumor invasion
and metastasis generation. However, a detailed molecular
mechanism underlying its anti-apoptotic activity is still
missing. Recently, a possible mechanism by which PVT1
inhibits cell death has been described in nasopharyngeal
carcinomas. In particular, PVT1 downregulates the
expression of cleaved caspase-9, caspase-7, and PARP,
inhibiting apoptosis and also promoting radiation
resistance132,133.
Circular RNAs
Circular RNAs (circRNAs) were identified more than 20
years ago, and for many years have just been considered as
secondary products of aberrant splicing processes134.
Only recently, with the advent of next-generation
sequencing, a large number of circRNAs has been iden-
tified, several of them showing high and stable expression.
Nearly 10% of genes transcribed in cells can produce
circRNAs.
CircRNAs are transcribed by RNA polymerase II (Pol
II), and they are generated by alternative splicing of pre-
mRNA, in which the 5′ and the 3′ ends are joined together
by a covalent bond, forming a single-strand continuous
loop structure in a process known as “backsplicing”135.
Moreover, several molecular mechanisms of action have
been proposed to characterize their role in different bio-
logical and pathological processes. In particular, circRNAs
are likely to function as miRNA sponges, to enhance the
transcription of their parental genes or acting as decoys or
scaffolds for proteins136,137.
The research on circRNAs is still in his infancy and their
specific functions in several physiological processes and in
the pathogenesis of human diseases is still largely
unknown. However, recently high-throughput sequencing
Fig. 4 lncRNAs with an anti-apoptotic activity and relative molecular mechanisms. a CCAT is an oncogene that protects from cell death by up-
regulating the expression of MYC. b p63, SOX2, and CCAT form a trimeric complex, which in turn binds the promoter region of EGFR and positively
upregulates its expression. This results in sustaining cell survival. c FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in
order to modulate the transcription of a number of genes involved in cell death. CCAT colon cancer-associated transcript, MYC Myc proto-oncogene,
SOX2 sex determining region box-2, EGFR epithelial growth factor receptor, FAL1 focally amplified LncRNA on chromosome 1, BMI1 polycomb
complex protein BMI1.
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studies on clinical tumor samples showed a deregulation
of circRNAs expression in tumors138,139. In particular,
their downregulation has been described in proliferative
cells across different tumor types, indicating that some
circRNAs may have tumor suppressive roles. Global
transcriptome analysis on 144 samples of localized pros-
tate cancer, identifying 76,311 circRNAs, showed a cor-
relation of circRNAs expression with tumor aggressivity,
suggesting that 171 circRNAs are essential to prostate
cancer cell proliferation140.
Overall, studies on clinical samples together with
in vitro experiments showed that circRNAs play a role in
several hallmarks of cancer having either tumor sup-
pressive or oncogenic functions141–143. To our knowledge,
no circRNAs from the literature have a clear and defined
role in cancer biology proven by in vitro or in vivo
experiments or by clinical data. However, we have decided
to describe one of the more studied circRNAs that has a
role in cell death regulation.
circFOXO3
circFOXO3 is a circular transcript of 1435 nucleotides
derived from the tumor suppressor gene FOXO3144.
Several expression profile studies indicated that cir-
cFOXO3 is downregulated in several tumors such as
breast and NSCLC, suggesting a possible role as a tumor
suppressor gene145,146. Both gain and loss of function
experiments showed that circFOXO3 function is asso-
ciated with the induction of apoptosis and with the inhi-
bition of cell-cycle progression and angiogenesis. At a
molecular level, ectopic expression of circFOXO3
decreases the interaction between FOXO3 and MDM2,
releasing FOXO3 from MDM2-dependent degradation,
therefore increasing FOXO3 activity, promoting PUMA
expression, and enhancing cell death147.
Perspectives and conclusions
During the last decades, we have witnessed considerable
developments in understanding the role of the regulatory
ncRNAs in the regulation of physiological processes as
well as in the pathogenesis of several diseases. Deregula-
tion of ncRNAs expression has been largely documented
during the initiation, progression, and dissemination of
cancer, and preclinical studies have shown that they can
be used as diagnostic and prognostic biomarkers. More
importantly, it has been documented that ncRNAs can be
released into the extracellular space and detected in body
fluids (blood or urine) as circulating ncRNAs, potentially
showing their application in liquid biopsies148. The clin-
ical application of ncRNAs is already under evaluation in
ongoing clinical trials trying to describe their role as
biomarkers for patient survival, metastasis development
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As from above, regulatory ncRNAs play a key role in
driving or preventing the process of tumorigenesis and
preclinical studies indicate that modulation of their
expression by mimetic or inhibitory oligonucleotides
might be a novel therapeutic approach for cancer therapy.
Indeed, a limited number of clinical trials using drugs
based on ncRNAs, especially on microRNAs, are evalu-
ating clinical safety, tolerability, and efficacy of this
approach (Table 2). Although therapeutic applications are
still at an early phase, a new chapter in the pharmacolo-
gical treatment of human diseases has started. The recent
approval of the RNA-targeting oligonucleotides drug
Spinraza for the treatment of spinal muscular atrophy by
FDA149 makes reasonable to believe that more ncRNAs-
based drugs will be soon available on the patient’s bedside.
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